Skip to main content

Table 1 Characteristics of randomized clinical trials investigating the role of blood pressure lowering on stroke recurrence.

From: Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis

Study Year Drug Type of Stroke Subjects (Treated, Control) Mean Follow-up Period (years) Decrease in BP with Treatment (sys/dia in mmHg)
BPLPRS [23] 2005 Perindopril + indapamide vs. placebo TIA, Isch, Hem 1520 (762, 758) 4 14/6
Dutch TIA [20] 1993 Atenolol vs. placebo TIA or non-disabling Isch 1473 (732, 741) 2.6 5.8/2.9
HOPE [33] 2000 Ramipril vs. placebo TIA or stroke NS 1013 (500, 513) 5 NS
HSCSG [18] 1974 Deserpidine + methyclothiazide vs. placebo TIA, Isch, Hem 452 (233, 219) 2.8 25/12.3
Martí Massó [19] 1990 Nicardipine vs. nothing TIA, RIND, Isch 264 (170, 94) 1 NS
PATS [21] 1995 Indapamide vs. placebo TIA, Isch, Hem 5665 (2841, 2824) 2.8 6.2/2.9
PRoFESS [13] 2008 Telmisartan vs. placebo Isch 20332 (10146, 10186) 2.5 3.8/2
PROGRESS [10] 2001 Perindopril + indapamide OR perindopril vs. placebo TIA, Isch, Hem 6105 (3051, 3054) 4 9/4
   Perindopril vs. placebo   2561a (1281, 1280)   5/3
   Perindopril + indapamide vs. placebo   3544a (1770, 1774)   12/5
SCOPE [24] 2005 Candesartan vs. placebo NS 193 (96, 97) 3.7 -0.4/1.5b
TEST [22] 1995 Atenolol vs. placebo NS 720 (372, 348) 2.5 4/3
  1. Hem, hemorrhagic stroke or intracerebral hemorrhage; Isch, ischemic stroke; NS, not specified in published report; RIND, reversible ischemic neurological defect; TIA, transient ischemic attack.
  2. a Part of the original 6,105 PROGRESS study participants.
  3. b Mean systolic blood pressure increased in treatment group.